Hudson Bay Capital Management
ALLO icon

Hudson Bay Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Hudson Bay Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,711
Closed -$35.9K – 1351
2026
Q1 		$35.9K Buy
+14,711
New +$29.5K ﹤0.01% 1288

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Hudson Bay Capital Management's ALLO Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Allogene Therapeutics (ALLO) in Q2 2026, closing a stake of 14,711 shares — an estimated $35.9K sold.

Hudson Bay Capital Management first reported a position in ALLO in Q1 2026 and held it in 1 quarter. The position peaked at $35.9K in Q1 2026. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining Allogene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 14,711 Allogene Therapeutics shares in Q2 2026, an estimated $35.9K.
  • Hudson Bay Capital Management first reported a position in Allogene Therapeutics in Q1 2026 and held it in 1 quarter.
  • Hudson Bay Capital Management's Allogene Therapeutics position peaked at $35.9K in Q1 2026.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.